Menu

1 / 36

Why Is Lexeo Therapeutics Stock Trading Higher Today? - Lexeo Therapeutics (NASDAQ:LXEO)

Top Stories Feed·Vandana Singh·about 3 hours ago
#9rjMtA1y
#benzinga#dose#pkp2#high#therapeutics
Reading 0:00
15s threshold

November 16, 2026 1:31 PM 2 min read

Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study

by Vandana Singh Benzinga Staff Writer

Follow

LXEOLexeo Therapeutics Inc

$3.087.14%

Stock Score Locked: Want to See it?

Benzinga Edge Rankings give you vital metrics on any stock – anytime.

Reveal Full Score Edge Rankings

MomentumN/A

GrowthN/A

QualityN/A

ValueN/A

Price Trend

ShortMediumLongOverview Lexeo Therapeutics Inc. (NASDAQ:LXEO) on Monday announced positive interim results from its ongoing HEROIC-PKP2 Phase 1/2 trial evaluating LX2020 in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) and outlined plans to launch a pivotal study in late 2027.

PKP2-ACM is an inherited heart muscle condition caused by a change, or variant, in the PKP2 gene.

The clinical-stage genetic medicine company dosed 10 participants, including three in Cohort 1 at a low dose (2×10^13 vg/kg) and seven in Cohorts 2 and 3 at a high dose (6×10^13 vg/kg).

By the October 15, 2026, data cutoff, nine…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.